Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CMC Biologics, RuiYi in MAb Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

CMC Biologics, RuiYi in MAb Development Pact

CMC will use CHEF1 system for cell line development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CMC Biologics has entered an agreement with RuiYi, Inc. to develop a cell line for RYI-008, an anti-IL-6 monoclonal antibody. CMC will use its CHEF1 high-productivity expression plasmid for the cell line development to optimize cell growth and protein expression in a rapid time frame. Financial terms were not disclosed.
 
“We are excited to work with CMC Biologics, a global contract manufacturing organization known for its technical excellence in biopharmaceutical development and cGMP manufacturing,” said Paul Grayson, president and chief executive officer of RuiYi. “The integrated services, including cell line development using the proprietary CHEF1 system, along with CMC’s responsive and collaborative interactive style, made CMC Biologics the obvious partner for this important global effort.”
 
“We are pleased with the opportunity to build a long-term relationship with RuiYi on the development of RYI-008. RYI-008 is an antibody with unprecedented potency and remarkable half-life, creating a significant opportunity to be a best in class product in the rapidly evolving field of IL-6 biology,” said Mark Sawicki, Ph.D., global vice president business development of CMC Biologics. “This agreement underscores our strategic focus on biologics development in emerging markets.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics